Accession Number:

ADA364317

Title:

Phase I Evaluation of Desbutyihalofantrine in Healthy Volunteers.

Descriptive Note:

Annual rept. 14 Sep 97-13 Sep 98

Corporate Author:

GEORGETOWN UNIV WASHINGTON DC

Personal Author(s):

Report Date:

1998-12-01

Pagination or Media Count:

256.0

Abstract:

Halofantrine HCl is an antimalarial drug approved by the FDA for the treatment of mild to moderate malaria caused by Plasm odium falciparum or Plasm odium vivaxl. The present study was designed to investigate the safety, tolerance and pharmacokinetics of halofantrine HCI given in multiple doses in a Phase I study as part of the overall development of halofantrine as a prophylactic antimalarial drug.

Subject Categories:

  • Medicine and Medical Research
  • Microbiology
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE